Heron Therapeutics (HRTX) Shares Outstanding (Weighted Average) (2010 - 2026)

Heron Therapeutics has reported Shares Outstanding (Weighted Average) for 17 years, with the latest figure at $189.6 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 23.56% year-over-year to $189.6 million; the trailing twelve-month figure through Mar 2026 stood at $189.6 million (up 23.56% YoY), and the FY2025 full-year result was $166.7 million, up 9.35% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $189.6 million, up from $166.7 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $189.6 million in Q1 2026, with the low at $102.1 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $139.5 million across 5 years, with a median of $151.2 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Weighted Average) soared 110466.56% — and 2025, when it grew 1.4%.
• Heron Therapeutics' Shares Outstanding (Weighted Average) stood at $108.9 million in 2022, then gained by 26.87% to $138.1 million in 2023, then gained by 10.36% to $152.4 million in 2024, then grew by 9.35% to $166.7 million in 2025, then rose by 13.76% to $189.6 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $189.6 million (Q1 2026), $166.7 million (Q4 2025), and $159.5 million (Q3 2025), per Business Quant data.